Home » Novoste Announces Restructuring, Staged Wind-Down of VBT Business
Novoste Announces Restructuring, Staged Wind-Down of VBT Business
Novoste announced that its board of directors has determined that its vascular brachytherapy (VBT) business is no longer viable and, as a result, has authorized a staged, wind-down of the business. The board has determined that this decision is necessary to preserve the company's cash resources and arises as a result of the continuing decline in revenue for the company's VBT product.
MENAFN (http://menafn.com/qn_news_story.asp?StoryId=CqHQ8ubKbmduZyJuZnZe)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct